Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Nanotechnology Programs at FDA

Nanotechnology Programs at FDA

                        Nanotechnology Guidance Documents
          Nanotechnology Task Force Home
          Science & Research
          Science and Research Special Topics
          Nanotechnology Programs at FDA
          Nanotechnology Partnerships at FDANanotechnology Programs at FDA Nanotechnology Partnerships at FDA
  
  	
    Share
    Post
    Linkedin

    Email
    PrintFDA's Nanotechnology Task Force Report of 2007 called for promoting and participating in collaborative efforts, to further understanding of biological interactions of nanoscale materials, and exploring opportunities to enable innovation using nanoscale materials to develop safe and effective products under its regulatory jurisdiction. Aligned with the need to promote and participate in such collaborations whereby stakeholders can leverage expertise and resources to stimulate innovation in this field, FDA has embarked on a number of Public-Private Partnerships (PPPs) under its public health mission. This site is intended to provide, in a transparent way, both a synopsis of its current collaborations in the field of nanotechnology and an opportunity for stakeholders to either join with us to expand existing collaborations or embark upon new ones with FDA, in the interest of public health.For more information about other federal agencies involved in nanotechnology, please visit the link to the National Nanotechnology Initiative web site.**FDA-NCI -NIST**Nanotechnology Characterization LaboratoryFDA-NCI-NIST Memorandum of UnderstandingThe U.S. Food and Drug Administration (FDA) partnered with the National Institute of Standards and Technology (NIST) and the National Cancer Institute (NCI) to establish the Nanotechnology Characterization Laboratory (NCL) to perform multidisciplinary testing, vital to the clinical translation of nanomedicine candidates. Under this partnership, NCL:Provides preclinical and early clinical characterization, pharmacokinetic, efficacy, and toxicity testing on a wide variety of nano-based formulations to support regulatory decision-makingProtocols are freely available onlineData acquired by NCL can be used to meet regulatory requirements for an Investigational New Drug (IND) or Investigational Device Exemption (IDE) filingCollaborates with FDA to design novel assays and assessment tools that complement regulatory evaluation and guidance developmentPerforms research and development on nanomedicines, including mechanistic studies, bioanalytical/physicochemical methods development, and nanotech reformulationFDA provides scientific input and guidance to the NCL on unmet regulatory needs, and serves on the NCL’s Scientific Oversight Committee.To learn more about NCL, visit: https://ncl.cancer.gov/**FDA-Johns Hopkins University**FDA-Johns Hopkins University Memorandum of UnderstandingThis Memorandum of Understanding between the U.S. Food and Drug Administration ("FDA") and Johns Hopkins University (the "Parties") is established to develop collaboration in the areas of education, research, and outreach.The objectives of this collaborative partnership include, development of a collaborative working relationship between the Parties, provision of exchange of graduate and undergraduate students, faculty, and personnel, for the purposes of advanced training and outreach, stimulation of cooperative activities, research, and information exchange in areas such as bioethics, development of training programs for FDA and potentially other Government agencies and industry in broad scientific areas such as biotechnology and bioethics, development of a broad-based collaboration in the area of nanotechnology, including, in particular, with the Institute of NanoBioTechnology at the Johns Hopkins University.**FDA-ANH NanoTechnology Initiative (FANTI)**FANTIFANTI MOUFDA is engaged in a collaboration with the Houston-based Alliance for NanoHealth (ANH) and its eight member institutions to help speed development of safe and effective medical products in the emerging field of nanotechnology.Under the FDA/ANH Nanotechnology Initiative, the FDA and ANH will work to expand knowledge of how nanoparticles behave and affect biologic systems, and to facilitate the development of tests and processes that might mitigate the risks associated with nanoengineered products. All outcomes from this public-private partnership will be placed in the public domain for the benefit of all stakeholders.ResourcesForYouNIH Public-Private Partnership Program

                                                                                  Content current as of:
      03/22/2018Nanotechnology Programs at FDA

          
                        Nanotechnology Guidance Documents
          Nanotechnology Task Force
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop